Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX -0.53%16 Cash Ratio is 103.50 as of Dec. 2025, which is 2021% above its 10-year median of 4.88. GuruFocus rates FRA:ECX with a GF Score™ of 16/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Epigenomics AG ranks better than 99.52% on this metric.
Epigenomics AG has a Cash Ratio of 103.50. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Epigenomics AG's Cash Ratio or its related term are showing as below:
FRA:ECX'
s Cash Ratio Range Over the Past 10 Years
Min: 1.5 Med: 4.88 Max: 103.5
Current: 103.5
During the past 13 years, Epigenomics AG's highest Cash Ratio was 103.50. The lowest was 1.50. And the median was 4.88.
FRA:ECX's Cash Ratio is ranked better than 99.52% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs FRA:ECX: 103.50
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Epigenomics AG Cash Ratio Related Terms
Epigenomics AG Cash Ratio Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Epigenomics AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a Cash Ratio of 103.50 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Epigenomics AG and its competitors. This is 2021% above median its historical median of 4.88. Over the past decade, Epigenomics AG's Cash Ratio has ranged from 1.50 to 103.50. According to the industry distribution chart, Epigenomics AG ranks #1 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Epigenomics AG's Cash Ratio too high?
Epigenomics AG's current Cash Ratio of 103.50 is 2021% above median its 10-year median of 4.88. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 103.50. The Medical Diagnostics & Research industry median Cash Ratio is 0.98. Epigenomics AG's value of 103.50 is 10461.2% above this industry median. Based on the distribution chart, Epigenomics AG ranks #1 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Epigenomics AG has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #1 out of 208 companies for Cash Ratio. This places Epigenomics AG in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.98. Epigenomics AG's value of 103.50 is 10461.2% above this benchmark. Historically, Epigenomics AG's own Cash Ratio has ranged from 1.50 to 103.50 over the past decade. While the company's 10-year median is 4.88 vs. the industry median of 0.98, Epigenomics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigenomics AG's current Cash Ratio of 103.50 is 10461.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current Cash Ratio is 103.50, which is 2021% above median its own 10-year median of 4.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.94 — trading 944.4% above its estimated fair value. The current Cash Ratio is 103.50, which is 2021% above median its 10-year median of 4.88 and 10461.2% above the Medical Diagnostics & Research industry median of 0.98. Epigenomics AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Cash Ratio is 103.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.94 is trading 944.4% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
Cash Ratio: 103.50 (2021% above median its 10-year median of 4.88)
GF Value™: €0.09 vs. price of €0.94 (944.4% above fair value)
Industry Position: 10461.2% above the Medical Diagnostics & Research median (#1 of 208)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
16GF Score
Get the complete analysis for FRA:ECX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
